Outcomes of <i>IDH1</i>- and <i>IDH2</i>-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Evan C. Chen(Dana-Farber Cancer Institute), Amir T. Fathi(University of Southern California), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Corey Cutler(Harvard University), John Koreth(Otsuka (Japan)), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Zachariah DeFilipp(Harvard University), Mahasweta Gooptu(Harvard University), Marlise R. Luskin(Dana-Farber Cancer Institute), Joseph H. Antin(Dana-Farber Cancer Institute), Rizwan Romee(Washington University in St. Louis), Robert J. Soiffer(Dana-Farber Cancer Institute), Areej El‐Jawahri(Massachusetts General Hospital), Ann‐Kathrin Eisfeld, Shuli Li(Unknown), Daniel Jones(The Ohio State University), Steven L. McAfee(Harvard University)
Cited by 0
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k